A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Research And Treatment 2012, 133: 1057-1065. PMID: 22418700, PMCID: PMC3387495, DOI: 10.1007/s10549-012-2003-y.Peer-Reviewed Original ResearchConceptsHER2-positive metastatic breast cancerErbB family blockerMetastatic breast cancerBreast cancer patientsAdverse eventsCancer patientsBreast cancerEastern Cooperative Oncology Group performance statusHER2-positive breast cancer patientsIrreversible ErbB family blockerMedian progression-free survivalTreatment-related adverse eventsPositive breast cancer patientsHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Common Terminology CriteriaMedian overall survivalObjective response ratePhase II studyProgression-free survivalGrowth factor receptor 2Single-arm studyPrior chemotherapy linesPromising clinical activityFactor receptor 2